Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 4/20 | 0.40 |
| ▸ | CES1 | P23141 | 4/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4601205 | 0.98 | DNM1 (0.50) | DNM1EPHX2ALDH1A1S1PR2S1PR1 | |
| SCHEMBL16658724 | 0.98 | DNM1 (0.50) | DNM1EPHX2ALDH1A1S1PR2S1PR1 | |
| SCHEMBL16658678 | 0.98 | DNM1 (0.50) | DNM1EPHX2ALDH1A1S1PR2S1PR1 | |
| SCHEMBL16658679 | 0.98 | DNM1 (0.50) | DNM1EPHX2ALDH1A1S1PR2S1PR1 | |
| SCHEMBL3440790 | 0.98 | DNM1 (0.50) | DNM1EPHX2ALDH1A1S1PR2S1PR1 | |
| SCHEMBL6949703 | 0.98 | DNM1 (0.50) | DNM1EPHX2ALDH1A1S1PR2S1PR1 | |
| SCHEMBL2180094 | 0.98 | DNM1 (0.50) | DNM1EPHX2ALDH1A1S1PR2S1PR1 | |
| SCHEMBL1902069 | 0.98 | DNM1 (0.50) | DNM1EPHX2ALDH1A1S1PR2S1PR1 | |
| SCHEMBL18660081 | 0.98 | DNM1 (0.50) | DNM1EPHX2ALDH1A1S1PR2S1PR1 | |
| SCHEMBL2485136 | 0.98 | DNM1 (0.50) | DNM1EPHX2ALDH1A1S1PR2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370486-A1 | BRUSH COPOLYMERS | Bausch & Lomb Incorporated (US) | 2011-10-05 | — | — | EP | claimed |
| WO-2010078149-A1 | BRUSH COPOLYMERS | BAUSCH & LOMB INCORPORATED (US) | 2010-07-08 | — | — | WO | claimed |
| EP-3596075-B1 | AZAINDOLES AS INHIBITORS OF HPK1 | HOFFMANN LA ROCHE (CH) | 2023-10-11 | — | — | EP | disclosed |
| CN-115232451-B | Polyhydroxyalkanoate material or product capable of being rapidly crystallized and preparation method thereof | 四川大学 | 2023-08-04 | — | — | CN | disclosed |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2022-06-07 | — | — | US | disclosed |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-03-19 | — | — | US | disclosed |
| US-20170102627-A1 | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND ELECTROPHOTOGRAPHIC APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2017-04-13 | — | — | US | disclosed |
| EP-3148646-A1 | COSMETIC COMPOSITION FOR MAKE UP AND FOR TAKING CARE OF KERATIN MATERIALS | L'Oréal (FR) | 2017-04-05 | — | — | EP | disclosed |
| US-9345709-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-05-24 | — | — | US | disclosed |
| EP-2970104-A1 | BICYCLIC ANALGESIC COMPOUNDS | Kalyra Pharmaceuticals Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-1379238-A1 | FAVORABLE MODULATION OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH-RELATED QUALITY-ADJUSTED TIME-TO-PROGRESSION OF DISEASE IN PATIENTS WITH PROSTATE CANCER | Abbott Laboratories (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030092757-A1 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | ABBOTT LABORATORIES | 2003-05-15 | — | — | US | disclosed |
| EP-1307175-A2 | HAIR STYLING COMPOSITION | Unilever Plc (GB) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002085351-A1 | FAVORABLE MODULATION OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH-RELATED QUALITY-ADJUSTED TIME-TO-PROGRESSION OF DISEASE IN PATIENTS WITH PROSTATE CANCER | ABBOTT LABORATORIES (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002011686-A2 | HAIR STYLING COMPOSITION | UNILEVER PLC (GB) | 2002-02-14 | — | — | WO | disclosed |
| US-5990070-A | GRANULAR LAUNDRY DETERGENT WITH HYDROGEN PEROXIDE SOURCE, MOISTURE-ACTIVATED HYDROPHOBIC BLEACH ACTIVATOR CELLULAR MATRIX MICROCAPSULES COMPRISING POLYSACCHARIDE OR POLYHYDROXY COMPOUND ENCAPSULATING ACTIVATOR IN SPECIFIC MOLAR RATIO | THE PROCTER & GAMBLE COMPANY (US) | 1999-11-23 | — | — | US | disclosed |
| US-5905067-A | COMPLEXED WITH A CYCLODEXTRIN; SUITABLE FOR IN CLEANING PRODUCTS SUCH AS GRANULAR LAUNDRY DETERGENTS, GRANULAR AUTOMATIC DISHWASHER DETERGENTS, GRANULAR HARD SURFACE CLEANERS AND LAUNDRY BARS | PROCTER & GAMBLE COMPANY (US) | 1999-05-18 | — | — | US | disclosed |
| EP-0859047-A2 | A system for delivering hydrophobic liquid bleach activators | THE PROCTER & GAMBLE COMPANY (US) | 1998-08-19 | — | — | EP | disclosed |
| WO-1998012143-A1 | PROCESS FOR CLEANING WASTEWATER AND RECIRCULATING WATER IN PAPER PRODUCTION, DE-INKING AND BLEACHING OF PULP | BASF AKTIENGESELLSCHAFT (DE) | 1998-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092757-A1 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | KLK3, ACP3, BPHL | DNM1 2525/4885EPHX2 4249/4885ALDH1A1 1863/4885 |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | HMOX1, CD209, HMOX2 | DNM1 3539/4885EPHX2 776/4885ALDH1A1 115/4885 |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, EGFR | DNM1 2451/4885EPHX2 1290/4885ALDH1A1 1646/4885 |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | WEE1, WEE2, EGFR | DNM1 2451/4885EPHX2 1290/4885ALDH1A1 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.